JP2019506394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506394A5 JP2019506394A5 JP2018538085A JP2018538085A JP2019506394A5 JP 2019506394 A5 JP2019506394 A5 JP 2019506394A5 JP 2018538085 A JP2018538085 A JP 2018538085A JP 2018538085 A JP2018538085 A JP 2018538085A JP 2019506394 A5 JP2019506394 A5 JP 2019506394A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- cdr3
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 81
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 24
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 23
- 210000004899 c-terminal region Anatomy 0.000 claims 17
- 210000002865 immune cell Anatomy 0.000 claims 17
- 230000004068 intracellular signaling Effects 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 206010014968 Ependymoma malignant Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 208000014534 anaplastic ependymoma Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 208000026436 grade III glioma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 206010035059 pineocytoma Diseases 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281533P | 2016-01-21 | 2016-01-21 | |
| US62/281,533 | 2016-01-21 | ||
| US201662431758P | 2016-12-08 | 2016-12-08 | |
| US62/431,758 | 2016-12-08 | ||
| PCT/IB2017/050108 WO2017125830A1 (en) | 2016-01-21 | 2017-01-10 | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177399A Division JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506394A JP2019506394A (ja) | 2019-03-07 |
| JP2019506394A5 true JP2019506394A5 (enExample) | 2020-02-20 |
| JP6823659B2 JP6823659B2 (ja) | 2021-02-03 |
Family
ID=57868301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538085A Active JP6823659B2 (ja) | 2016-01-21 | 2017-01-10 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
| JP2020177399A Active JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177399A Active JP7198797B2 (ja) | 2016-01-21 | 2020-10-22 | 上皮成長因子受容体変異体ｉｉｉを標的とするキメラ抗原受容体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10259876B2 (enExample) |
| EP (1) | EP3405481B1 (enExample) |
| JP (2) | JP6823659B2 (enExample) |
| KR (1) | KR102479606B1 (enExample) |
| CN (1) | CN108699124A (enExample) |
| AU (1) | AU2017208834B2 (enExample) |
| BR (1) | BR112018014585A2 (enExample) |
| CA (1) | CA2954014A1 (enExample) |
| DK (1) | DK3405481T5 (enExample) |
| EA (1) | EA201891641A1 (enExample) |
| ES (1) | ES2942362T3 (enExample) |
| IL (1) | IL260666B2 (enExample) |
| MX (1) | MX2018008978A (enExample) |
| MY (1) | MY192474A (enExample) |
| NZ (1) | NZ744821A (enExample) |
| PH (1) | PH12018501473B1 (enExample) |
| RU (1) | RU2751662C2 (enExample) |
| SA (1) | SA518392058B1 (enExample) |
| SG (2) | SG10202111458RA (enExample) |
| TW (2) | TWI755547B (enExample) |
| UA (1) | UA125252C2 (enExample) |
| WO (1) | WO2017125830A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| US10259876B2 (en) | 2016-01-21 | 2019-04-16 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant III |
| DK3405490T3 (da) | 2016-01-21 | 2022-01-10 | Pfizer | Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| WO2019195586A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| TW202020146A (zh) * | 2018-07-26 | 2020-06-01 | 大陸商南京傳奇生物科技有限公司 | 含nef之t細胞及其產生方法 |
| CN109265561B (zh) * | 2018-09-25 | 2021-05-25 | 山东兴瑞生物科技有限公司 | 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| PE20211915A1 (es) * | 2018-12-01 | 2021-09-28 | Allogene Therapeutics Inc | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso |
| TWI881476B (zh) * | 2018-12-21 | 2025-04-21 | 瑞士商赫孚孟拉羅股份公司 | 結合cd3之抗體 |
| AU2020209991B2 (en) * | 2019-01-17 | 2024-11-14 | Immunocore Limited | Formulations |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| CN113710697A (zh) * | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| EP3994173A1 (en) * | 2019-07-02 | 2022-05-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind egfrviii and their use |
| US20220288118A1 (en) * | 2019-07-31 | 2022-09-15 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| EP4031583A4 (en) * | 2019-09-16 | 2023-11-15 | Fred Hutchinson Cancer Center | CHIMERIC RECEPTOR PROTEINS AND THEIR USES |
| AU2020358898B2 (en) * | 2019-10-01 | 2025-10-16 | Epsilogen Ltd | Hybrid antibody |
| EP4081537A1 (en) * | 2019-12-23 | 2022-11-02 | Cellectis | New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy |
| CN111019959B (zh) * | 2019-12-30 | 2022-09-13 | 北京立康生命科技有限公司 | 一种体外转录mRNA的核苷酸分子、呈递细胞及应用 |
| WO2021150936A1 (en) * | 2020-01-22 | 2021-07-29 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| KR20230142470A (ko) | 2021-01-29 | 2023-10-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃 |
| EP4372088A4 (en) * | 2021-07-16 | 2025-07-23 | Noile Immune Biotech Inc | ANTI-EGFRVIII ANTIGEN, POLYPEPTIDE, CELL EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR CONTAINING A SEQUENCE OF BASES ENCODING SAID POLYPEPTIDE |
| KR20240070579A (ko) * | 2021-09-29 | 2024-05-21 | 내셔날 리서치 카운실 오브 캐나다 | 인간화 항-egfrviii 항체 및 이의 항원 결합 단편 |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| WO2024027835A1 (zh) * | 2022-08-05 | 2024-02-08 | 北京鼎成肽源生物技术有限公司 | 靶向EGFRvIII的抗体及其在细胞免疫治疗的应用 |
| CN116284435A (zh) * | 2022-09-19 | 2023-06-23 | 卡瑞济(北京)生命科技有限公司 | EGFRvIII嵌合抗原受体及其用途 |
| CN120936371A (zh) * | 2023-03-30 | 2025-11-11 | 诺沃库勒有限责任公司 | 用于使用肿瘤治疗电场和嵌合抗原受体(car)免疫细胞治疗癌症的组合物、系统和方法 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN117659196B (zh) * | 2023-12-12 | 2024-08-23 | 成都优赛诺生物科技有限公司 | 一种靶向cd7的单域抗体、嵌合抗原受体及其应用 |
| CN119912588B (zh) * | 2025-04-01 | 2025-08-12 | 浙江大学 | 嵌合抗原受体、人诱导多能干细胞、髓系前体细胞样巨噬细胞及其制备方法 |
| CN120248142B (zh) * | 2025-06-06 | 2025-09-12 | 上海兴瑞一达生物科技有限公司 | 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| EP0651805B1 (en) | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CN1427891A (zh) * | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| JP2013544082A (ja) | 2010-10-27 | 2013-12-12 | セレクティス | 二本鎖破断−誘導変異誘発の効率を増大させる方法 |
| US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| JP6154895B2 (ja) | 2012-06-07 | 2017-06-28 | デューク ユニバーシティー | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 |
| CN104583230A (zh) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2968552B1 (en) | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| AU2014266833B2 (en) | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| RS65484B1 (sr) | 2013-05-13 | 2024-05-31 | Cellectis | Cd19 specifični himerni antigenski receptor i njegove primene |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| ES2718399T3 (es) | 2013-07-09 | 2019-07-01 | Univ Duke | Moléculas que se acoplan a anticuerpos EGFRVIII biespecíficas humanas |
| WO2015018527A1 (en) | 2013-08-07 | 2015-02-12 | Affimed Therapeutics Ag | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| AU2014368383B2 (en) | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| RU2017102769A (ru) | 2014-07-29 | 2018-08-28 | Пфайзер Инк. | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| US10259876B2 (en) | 2016-01-21 | 2019-04-16 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant III |
| DK3405490T3 (da) | 2016-01-21 | 2022-01-10 | Pfizer | Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf |
-
2017
- 2017-01-10 US US15/402,760 patent/US10259876B2/en active Active
- 2017-01-10 SG SG10202111458RA patent/SG10202111458RA/en unknown
- 2017-01-10 PH PH1/2018/501473A patent/PH12018501473B1/en unknown
- 2017-01-10 UA UAA201808794A patent/UA125252C2/uk unknown
- 2017-01-10 JP JP2018538085A patent/JP6823659B2/ja active Active
- 2017-01-10 BR BR112018014585A patent/BR112018014585A2/pt not_active Application Discontinuation
- 2017-01-10 KR KR1020187023865A patent/KR102479606B1/ko active Active
- 2017-01-10 SG SG11201805872SA patent/SG11201805872SA/en unknown
- 2017-01-10 RU RU2018130088A patent/RU2751662C2/ru active
- 2017-01-10 ES ES17701190T patent/ES2942362T3/es active Active
- 2017-01-10 MX MX2018008978A patent/MX2018008978A/es unknown
- 2017-01-10 EP EP17701190.5A patent/EP3405481B1/en active Active
- 2017-01-10 WO PCT/IB2017/050108 patent/WO2017125830A1/en not_active Ceased
- 2017-01-10 EA EA201891641A patent/EA201891641A1/ru unknown
- 2017-01-10 DK DK17701190.5T patent/DK3405481T5/da active
- 2017-01-10 MY MYPI2018702481A patent/MY192474A/en unknown
- 2017-01-10 CN CN201780012883.XA patent/CN108699124A/zh active Pending
- 2017-01-10 NZ NZ744821A patent/NZ744821A/en unknown
- 2017-01-10 CA CA2954014A patent/CA2954014A1/en active Pending
- 2017-01-10 TW TW107120550A patent/TWI755547B/zh active
- 2017-01-10 AU AU2017208834A patent/AU2017208834B2/en active Active
- 2017-01-10 TW TW106100738A patent/TWI634125B/zh active
-
2018
- 2018-07-19 SA SA518392058A patent/SA518392058B1/ar unknown
- 2018-07-19 IL IL260666A patent/IL260666B2/en unknown
-
2019
- 2019-01-23 US US16/255,348 patent/US11267892B2/en active Active
-
2020
- 2020-10-22 JP JP2020177399A patent/JP7198797B2/ja active Active
-
2022
- 2022-01-27 US US17/586,321 patent/US20220227874A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506394A5 (enExample) | ||
| JP2019506398A5 (enExample) | ||
| RU2018130088A (ru) | Химерные антигенные рецепторы, нацеливающиеся на вариант iii рецептора эпидермального фактора роста | |
| JP2017506217A5 (enExample) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2017140051A5 (enExample) | ||
| HRP20240926T1 (hr) | Claudin-6-specifični imunoreceptori i epitopi t stanica | |
| JP2016508725A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2017527274A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| WO2006099141A3 (en) | Anti-mesothelin antibodies | |
| WO2015197016A1 (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2017104113A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| JP2021501567A5 (enExample) | ||
| MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
| CR20200325A (es) | Constructo de anticuerpo biespecífico dirigido a muc17 y cd3 | |
| Ahmed et al. | Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody | |
| FI3806895T3 (fi) | Kasvainkudosta sitovia vasta-aineita ja niiden diagnostisia ja terapeuttisia käyttöjä | |
| HRP20180917T1 (hr) | Novi fragmenti protutijela, pripravci i njihova upotreba | |
| CN104877028A (zh) | 抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用 | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 |